Oncotelic Therapeutics

Oncotelic develops PDAOAI, a knowledge-discovery platform for drug discovery and AI-powered GMP manufacturing.

: 22
: Public company
: 1996
: Aguora Hills, CA, USUnited States

Library

oncotelic.comCrawled Oct 16, 2026

Blog

1 page

Blog/blog

About

1 page

About us/about-us

Contact

1 page

Contact/contact

Homepage

1 page

Homepage/

Coverage

14 items

Oncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer Signatureglobenewswire.com/news-release/2026/10/26/3388030/0/en/oncotelic-announces-pdaoai-identification-of-a-four-gene-liver-cancer-signature.html
Oncotelic uses its PDAOAI platform to discover a four-gene signature linked to liver cancer. The approach integrates AI-driven literature review with gene-expression data to support the development of Sapu003. Researchers aim to refine precision oncology by targeting these biomarkers.
Oct 2026GlobeNewswireNews article
Oncotelic Therapeutics Highlights Four-Gene mTOR Signature at 22nd Drug Discovery Strategic Summitkalkinemedia.com/us/news/announcements/oncotelic-therapeutics-highlights-four-gene-mtor-signature-at-22nd-drug-discovery-strategic-summit
Oncotelic Therapeutics presents a **four-gene mTOR signature** at the **22nd Drug Discovery Strategic Summit**, focusing on potential biomarkers for targeted cancer therapies. The company’s research aims to refine precision medicine approaches by identifying genetic patterns linked to mTOR pathway activity. This presentation underscores Oncotelic’s ongoing efforts to advance drug discovery in oncology through molecular insights.
Oct 2026kalkinemedia.comNews article
Oncotelic Keynote to Highlight Partition and Aggregation as a Fundamental Principle for AI Enabled Discoverymorningstar.com/news/globe-newswire/9849309/oncotelic-keynote-to-highlight-partition-and-aggregation-as-a-fundamental-principle-for-ai-enabled-discovery
Oncotelic’s Saran Saund presents a keynote linking **partition and aggregation** to AI-driven drug discovery, leveraging the company’s **PDAOAI intellectual property**. The talk outlines plans for **100 billion biological vectors** and introduces **Fastbot/Membot**, a platform granting individual researchers direct access. A case study on **HCC (hepatocellular carcinoma)** research will also be featured.
Oct 2026Morningstar, Inc.News article
PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026globenewswire.com/news-release/2026/10/05/3374486/0/en/pdaoai-opens-bio-reboot-collaboration-and-showcases-partitioned-literature-aggregation-at-drug-discovery-2026.html
PDAOAI launches a collaboration with **BIO REBOOT** to integrate its AI-driven drug discovery platform, connecting computational tools with biotech development. The company also demonstrates its **Partitioned Literature Aggregation** technology at **Drug Discovery 2026**, targeting scientists, developers, and founders in the biotech sector. The platform aims to streamline drug discovery workflows by merging AI analysis with real-world research data.
Oct 2026GlobeNewswireNews article